
Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.
This review of the month of September highlights some of the most significant dermatology headlines.
In September 2025, a wide range of developments have transpired in the field of dermatology, including new research into dermatologic disease states and approvals of medications such as remibrutinib and guselkumab by the






